- Home
- CD vs INBX Comparison
CD vs INBX Comparison
Compare CD & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.2M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CD | INBX |
|---|---|---|
| Price | $7.39 | $80.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 232.0K | ★ 236.0K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $956,830.00 | ★ $1,400,000.00 |
| Revenue This Year | $949,544.10 | $563.00 |
| Revenue Next Year | $14.69 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.39 | N/A |
| 52 Week Low | $1.38 | $10.81 |
| 52 Week High | $36.77 | $94.47 |
Technical Indicators
Market Signals| Indicator | CD | INBX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.68 |
| Support Level | N/A | $79.00 |
| Resistance Level | N/A | $94.47 |
| Average True Range (ATR) | 0.00 | 6.11 |
| MACD | 0.00 | -1.56 |
| Stochastic Oscillator | 0.00 | 12.77 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.